PMID- 24091908
OWN - NLM
STAT- MEDLINE
DCOM- 20140730
LR  - 20211021
IS  - 1435-2451 (Electronic)
IS  - 1435-2443 (Linking)
VI  - 398
IP  - 8
DP  - 2013 Dec
TI  - Sorafenib treatment is save and may affect survival of recurrent hepatocellular 
      carcinoma after liver transplantation.
PG  - 1123-8
LID - 10.1007/s00423-013-1114-1 [doi]
AB  - INTRODUCTION: Recurrent hepatocellular carcinoma (HCC) after liver 
      transplantation (LT) is a rare but challenging condition. In most cases, the 
      recurrent tumor is presented with extrahepatic spread. Therefore, systemic 
      treatment with sorafenib has to be assessed. Because of a plethora of possible 
      drug interactions, e.g., with immunosuppressant or anti-infective therapy, safety 
      and feasibility of sorafenib treatment requires special attention. MATERIALS AND 
      METHODS: We retrospectively analyzed 18 patients who suffered from recurrent 
      advanced HCC after LT between January 2002 and December 2010 at the University 
      Hospital Heidelberg regarding safety of sorafenib treatment and survival. 
      RESULTS: Results showed that 8 patients were eligible for treatment with 
      sorafenib showing a median time to progression (TTP) of 4.5 months and an overall 
      survival of 9 months. Most common side effects were grades I and II diarrhea and 
      hand-foot syndrome (HFS) which could be managed by sorafenib dose reduction. No 
      grade III or IV adverse events (AEs) were noticed. No patient had to discontinue 
      treatment due to AEs. The ten patients not amenable for sorafenib treatment, due 
      to initial poor performance status or its deterioration after first line 
      treatment, were treated with surgical resection (n = 3), locoregional therapies 
      (n = 1), or palliative radiation therapy (n = 1). They showed a median overall 
      survival of 2.3 months. CONCLUSION: Sorafenib may represent a therapeutic option 
      for recurrent HCC after LT with manageable side effects. The clinical benefit of 
      sorafenib in this setting is promising but needs to be confirmed in a prospective 
      randomized trial.
FAU - Pfeiffenberger, Jan
AU  - Pfeiffenberger J
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, INF 410, 69120, Heidelberg, Germany.
FAU - Koschny, Ronald
AU  - Koschny R
FAU - Hoffmann, Katrin
AU  - Hoffmann K
FAU - Mehrabi, Arianeb
AU  - Mehrabi A
FAU - Schmitz, Anne
AU  - Schmitz A
FAU - Radeleff, Boris
AU  - Radeleff B
FAU - Stremmel, Wolfgang
AU  - Stremmel W
FAU - Schemmer, Peter
AU  - Schemmer P
FAU - Ganten, Tom M
AU  - Ganten TM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131004
PL  - Germany
TA  - Langenbecks Arch Surg
JT  - Langenbeck's archives of surgery
JID - 9808285
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Liver Neoplasms/*drug therapy
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Postoperative Complications
MH  - Retrospective Studies
MH  - Sirolimus/therapeutic use
MH  - Sorafenib
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2013/10/05 06:00
MHDA- 2014/07/31 06:00
CRDT- 2013/10/05 06:00
PHST- 2013/04/05 00:00 [received]
PHST- 2013/09/02 00:00 [accepted]
PHST- 2013/10/05 06:00 [entrez]
PHST- 2013/10/05 06:00 [pubmed]
PHST- 2014/07/31 06:00 [medline]
AID - 10.1007/s00423-013-1114-1 [doi]
PST - ppublish
SO  - Langenbecks Arch Surg. 2013 Dec;398(8):1123-8. doi: 10.1007/s00423-013-1114-1. 
      Epub 2013 Oct 4.